Study of Autologous Decidual-like Natural Killer Cells Therapy for Women with Infertility or Pregnancy Issues Due to Abnormal Uterine NK Cells

What this Trial Is About

This research aims to explore the effectiveness and duration of autologous decidual-like natural killer NK cells therapy in improving uterine NK cell dysfunction in women with infertility or a history of adverse pregnancy outcomes. It focuses on patients with abnormal uterine NK cell function and fertility needs, seeking to understand how this therapy might help with such reproductive challenges. The treatment involves collecting peripheral blood from each patient to isolate and culture autologous decidual-like NK cells in the laboratory. These cells are then infused into the patients uterus through intrauterine perfusion. If the uterine NK cell function improves within six months after the first treatment, the patient can attempt pregnancy, with follow-up of pregnancy outcomes. If there is no improvement, a second infusion of the same therapy may be given, with up to two treatments total. Participants will undergo continuous menstrual blood analysis for six months to monitor uterine NK cell function after treatment. Researchers will also track pregnancy outcomes, including clinical pregnancy, ongoing pregnancy, live birth, preeclampsia, and fetal growth restriction for up to one year after therapy completion. The study includes safety and effectiveness assessments during this follow-up period, with a total participation duration extending to about one year after treatment.

Autologous Decidual-like Natural Killer Cells Therapy for Infertility or Adverse Pregnancy History